Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track.
StockNews.com initiated coverage on shares of Selecta Biosciences (NASDAQ:SELB – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the stock. Several other research firms have also recently weighed in on SELB. HC Wainwright reaffirmed a buy rating and set a $5.00 price objective on shares of Selecta […]
Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year […]
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) have earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year target […]
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB – Get Free Report) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year […]